Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05857891
NA

The Effect of Erythropoietin on Alveolar Fluid Clearance in Patients With Acute Respiratory Distress Syndrome

Sponsor: Second Affiliated Hospital of Wenzhou Medical University

View on ClinicalTrials.gov

Summary

Acute respiratory distress syndrome (ARDS) is a common acute and critical disease in clinic. The clinical mortality is as high as 30%-40%. At present, there is no specific treatment. Erythropoietin (EPO), also known as erythrocyte- stimulating factor, erythropoietin, has a certain amount in normal human body, mainly synthesized by liver in infants and kidneys in adults, which can stimulate erythropoiesis. In recent years, more and more studies have shown that high-dose exogenous EPO administration has benefit effects on multi-organ protection. Therefore, we designed this prospective, double-blind, placebo-controlled trial for defecting EPO on the alveolar fluid clearance of ARDS. The study mainly answers the following questions: Does human erythropoietin accelerate the resolution of alveolar edema in ARDS? Is there any effect on hospital survival? The study will draw conclusions by comparing the control group with the experimental group.

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

40

Start Date

2023-05-20

Completion Date

2027-03-31

Last Updated

2023-05-15

Healthy Volunteers

No

Interventions

DRUG

Human erythropoietin injection

Each subject in the test group received 40000iu of human erythropoietin intravenously

DRUG

0.9%NaCl

Each subject in the control group was injected with an equal volume of 0.9%NaCl

Locations (1)

SAHWenzhouMU

Wenzhou, Zhejiang, China